The Rest Of Europe In Vitro Diagnostics (IVD) Quality Control Market was valued at $57.5 Million in 2025 and projected to reach to $71.3 Million by 2030, representing a compound annual growth rate of CAGR 4.4%. Rest of Europe's IVD Quality Control Market is positioned for steady growth as healthcare systems across the region prioritize diagnostic accuracy and regulatory compliance.
Rest of Europe's IVD Quality Control Market is valued at USD 57.5 million in 2025, with steady expansion anticipated through 2030 as regulatory frameworks strengthen across non-major European markets.
The region demonstrates a CAGR of 4.4% from 2025 to 2030, reaching USD 71.3 million by forecast end, reflecting moderate but consistent market maturation driven by compliance demands and diagnostic infrastructure development.
Increasing harmonization of IVD regulations across Rest of Europe, including IVDR compliance requirements, is propelling demand for quality control solutions among diagnostic laboratories and manufacturers.
Rising diagnostic testing volumes, expanding healthcare expenditures, and growing adoption of advanced quality assurance protocols are key factors supporting sustainable growth in Rest of Europe's IVD quality control sector.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | MOLECULAR DIAGNOSTICS (Technology) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 5.5% from 2025 to 2030 |
| Largest Segment | QUALITY CONTROL PRODUCTS (Product & Service) |
| Market Size Base Year (Billions) | ~USD 1.65 (2025) |
| Revenue Forecast (Billions) | ~USD 2.15 (2030) |
| Segments Covered | Product & Service, Type, Technology, Manufacturer Type, End User |
5 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| BIOMERIEUX S.A. | France | Public Company | Clinical microbiology (VITEK, culture media, ID/AST, BACT/ALERT),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS),Immunoassays and biomarkers (VIDAS, Hybiome CLIA, sepsis markers), |
| CEPHEID INC. | United States | Private Company | GeneXpert instruments and Xpert test cartridges,SmartCycler systems and assays,Collaborative and program-based solutions (e.g., TB, Ebola, USPS BDS), |
| IMMUCOR, INC. | United States | Private Company | Transfusion (serology instruments and reagents),Transplant & Molecular (HLA, HEA/HPA typing, Array Imaging System),Platelet-focused and specialty coagulation products, |
| DIASORIN | Italy | Public Company | Immunodiagnostics – Infectious and Gastrointestinal Diseases,Immunodiagnostics – Endocrinology and Metabolic Disorders,Oncology and Tumor Markers, |
| UNILABS | Switzerland | Private Company | Core laboratory testing,Medical imaging services,Pathology and centres of excellence, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics,Life Science Research Instruments and Reagents,Other and Services, |
| THERMO FISHER SCIENTIFIC, INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| ABBOTT | United States | Public Company | Diagnostic Products (core lab, rapid, molecular, cardiometabolic, drug testing),Medical Devices (cardiovascular, diabetes care, neuromodulation),Nutritional Products (pediatric, adult, infant formula), |
| LGC LIMITED | South Korea | Public Company | Ethylene-based synthetic resins (EVA, HDPE, LDPE, LLDPE, POE, metallocene PE, UNIQABLE),Styrene-based resins (ABS, ASA, EPS, PS, SAN),Polycarbonate and polypropylene, |
| SIEMENS HEALTHINEERS AG | Germany | Public Company | Imaging,Diagnostics,Varian (Oncology), |
| QUIDELORTHO CORPORATION | United States | Public Company | Labs (clinical chemistry and immunoassay),Transfusion Medicine,Point of Care (professional and OTC), |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and related solutions),Life Sciences (research tools and genomic medicines),Diagnostics (clinical instruments and consumables), |
| SYSMEX CORPORATION | Japan | Public Company | Hematology analyzers and reagents (XN-Series, XN-V, ProCyte Dx),Coagulation systems and reagents,Blood gas, electrolyte, and urinalysis analyzers, |
| BIO-TECHNE CORPORATION | United States | Public Company | Protein Sciences reagents (cytokines, growth factors, antibodies, small molecules, sera, cell selection),Proteomic and protein analysis instruments and immunoassays,Diagnostics products, controls, calibrators, and assays, |
| MICROBIX BIOSYSTEMS INC. | Canada | Public Company | Antigen and test ingredient business,QAPs branded test controls and quality assessment products,DxTM viral transport medium, |
| GRIFOLS, S.A. | Spain | Public Company | Biopharma (plasma-derived medicines),Diagnostic,Bio Supplies, |
bioMérieux S.A. is a French public company founded in 1963 that employs 14,894 people. The company operates in the diagnostics and life sciences sector.
Cepheid Inc. is a private company founded in 1996 in the United States with 1,700 employees. The company specializes in molecular diagnostics and infectious disease testing.
Immucor, Inc. is a private company founded in 1982 in the United States with 1,125 employees. The company focuses on blood bank and transfusion diagnostics.
DiaSorin is an Italian public company founded in 1968 with 3,242 employees. The company operates in the in vitro diagnostics sector.
Unilabs is a private company founded in 1987 in Switzerland with 1,897 employees. The company provides laboratory and diagnostic services.
Bio-Rad Laboratories, Inc. is a public company founded in 1952 in the United States with 7,450 employees. The company develops and manufactures life science research and clinical diagnostics products.
Thermo Fisher Scientific, Inc. is a public company founded in 1956 in the United States with 125,000 employees. The company is a global leader in serving science with laboratory equipment, reagents, and analytical instruments.
Abbott is a public company founded in 1888 in the United States with 115,000 employees. The company operates in diagnostics, medical devices, pharmaceuticals, and nutritional products.
LGC Limited is a public company founded in 1947 in South Korea with 14,019 employees. The company provides testing, proficiency testing, and reference materials services.
Siemens Healthineers AG is a public company founded in 1896 in Germany with 72,369 employees. The company provides medical imaging, laboratory diagnostics, and point-of-care testing solutions.
QuidelOrtho Corporation is a public company founded in 1979 in the United States with 6,500 employees. The company develops and manufactures rapid diagnostic tests and molecular testing solutions.
Danaher Corporation is a public company founded in 1969 in the United States with 59,000 employees. The company operates across diagnostics, life sciences, and environmental and applied solutions segments.
Sysmex Corporation is a public company founded in 1968 in Japan with 10,861 employees. The company manufactures hematology analyzers and other in vitro diagnostic systems.
Bio-Techne Corporation is a public company founded in 1976 in the United States with 3,100 employees. The company develops and manufactures life science tools and bioanalytical instruments.
Microbix Biosystems Inc. is a public company founded in 1988 in Canada with 100 employees. The company produces quality control materials and reference standards for diagnostics.
Grifols, S.A. is a public company founded in 1909 in Spain with 25,000 employees. The company specializes in blood plasma derivatives and diagnostic products.
Latin America's IVD Quality Control Market is valued at USD 57.5 million in 2025.
Latin America's IVD Quality Control Market is projected to reach USD 71.3 million by 2030.
Latin America's IVD Quality Control Market is growing at a CAGR of 4.4% from 2025 to 2030.
Latin America's market growth is driven by regulatory compliance requirements, expanding laboratory infrastructure, healthcare modernization, and increased diagnostic testing volumes.
Latin America's 4.4% CAGR is slightly below the global 5.5% CAGR, reflecting regional economic conditions and varying adoption rates of advanced quality control technologies.
The study involved major activities in estimating the current market size for the global IVD quality controls market.
Exhaustive secondary research was done to collect information on the IVD quality controls market. The next step was to validate these findings, assumptions, and sizing estimates with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the IVD quality controls market.
The four steps involved in estimating the market size are as follows:
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
The following is a breakdown of the primary respondents:
Note 1: Others include sales, marketing, and product managers.
Note 2: Companies are classified into tiers based on their total revenue. Here’s the breakdown of tiers: Tier 1 = > USD 100 million, tier 2 = USD 10 million to USD 100 million, and tier 3 = < USD 10 million
To know about the assumptions considered for the study, download the pdf brochure
Both the top-down and bottom-up approaches were used to estimate and validate the IVD quality controls market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size included the following:

After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
IVD quality controls are standardized materials used to monitor, evaluate, and ensure the accuracy, reliability, and precision of diagnostic testing processes in clinical laboratories. These controls are designed to mimic patient samples and are produced from human-derived matrices such as serum, plasma, urine, or whole blood. IVD quality controls provide a benchmark for validating test system performance, detecting errors, and ensuring regulatory compliance across diverse diagnostic platforms.
Full forecast, segment splits, and company analysis for all In Vitro Diagnostics (IVD) Quality Control Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report